Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia

American Journal of Respiratory and Critical Care Medicine

Volumn 184, Issue 3, 2011, Pages 312-316

  Chen, Dennis ^a   Restrepo, Marcos I ^a,b   Fine, Michael J ^d,e   Pugh, Mary Jo V ^a   Anzueto, Antonio ^a,b   Metersky, Mark L ^c   Nakashima, Brandy ^a   Good, Chester ^d,e   Mortensen, Eric M ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic obstructive pulmonary disease; Inhaled corticosteroids; Mortality; Pneumonia

Indexed keywords

CORTICOSTEROID; HYPERTENSIVE FACTOR;

AGED; ARTICLE; ARTIFICIAL VENTILATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG USE; FEMALE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; AGED; FEMALE; HOSPITALS, VETERANS; HUMANS; INCIDENCE; MALE; OBSERVATION; PNEUMONIA; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TREATMENT OUTCOME; UNITED STATES;

EID: 80051556207     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201012-2070OC     Document Type: Article

References (36)

1. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349: 1436-1442. (Pubitemid 27212192)
2. Pauwels RA, Buist AS, Ma P, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respir Care 2001;46:798-825. (Pubitemid 33759920)
3. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-456. (Pubitemid 36173708)
4. Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300:2407-2416.
5. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 2009;169:219-229.
6. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007;176:162-166. (Pubitemid 47057852)
7. Almirall J, Bolibar I, Balanzo X, Gonzalez CA. Risk factors for community-acquired pneumonia in adults: a population-based case-control study. Eur Respir J 1999;13:349-355. (Pubitemid 29086832)
8. Farr BM, Bartlett CL, Wadsworth J, Miller DL. Risk factors for community-acquired pneumonia diagnosed upon hospital admission. British Thoracic Society Pneumonia Study Group. Respir Med 2000; 94:954-963.
9. Rello J, Rodriguez A, Torres A, Roig J, Sole-Violan J, Garnacho- Montero J, de la Torre MV, Sirvent JM, Brodi M. Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. Eur Respir J 2006;27:1210-1216. (Pubitemid 44914306)
10. Restrepo MI, Mortensen EM, Pugh JA, Anzueto A. COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur Respir J 2006;28:346-351. (Pubitemid 44914234)
11. Tejerina E, Frutos-Vivar F, Restrepo MI, Anzueto A, Palizas F, Gonzalez M, Apezteguia C, Abroug F, Matamis D, Bugedo G, et al. Prognosis factors and outcome of community-acquired pneumonia needing mechanical ventilation. J Crit Care 2005;20:230-238. (Pubitemid 41505340)
12. Malo de Molina R, Mortensen EM, Restrepo MI, Copeland LA, Pugh MJ, Anzueto A. Inhaled corticosteroid use is associated with lower mortality for subjects with chronic obstructive pulmonary disease and hospitalized with pneumonia. Eur Respir J, 2010;36:751-757.
13. Brown SH, Lincoln MJ, Groen PJ, Kolodner RM. VistA-US Department of Veterans Affairs national-scale HIS. Int J Med Inform 2003;69:135-156. (Pubitemid 38373274)
14. Marrie TJ, Durant H, Sealy E. Pneumonia-the quality of medical records data. Med Care 1987;25:20-24. (Pubitemid 17010473)
15. Whittle J, Fine MJ, Joyce DZ, Lave JR, Young WW, Hough LJ, Kapoor WN. Community-acquired pneumonia: can it be defined with claims data? Am J Med Qual 1997;12:187-193. (Pubitemid 127447173)
16. Aronsky D, Haug PJ, Lagor C, Dean NC. Accuracy of administrative data for identifying patients with pneumonia. Am J Med Qual 2005; 20:319-328. (Pubitemid 41771782)
17. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-619.
18. Southern DA, Quan H, Ghali WA. Comparison of the Elixhauser and Charlson/Deyo methods of comorbidity measurement in administrative data. Med Care 2004;42:355-360.
19. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47:1245-1251. (Pubitemid 24361532)
20. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001;154: 854-864. (Pubitemid 33000813)
21. Mortensen EM, Coley CM, Singer DE, Marrie TJ, Obrosky DS, Kapoor WN, Fine MJ. Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med 2002;162:1059-1064. (Pubitemid 34492537)
22. Sohn MW, Arnold N, Maynard C, Hynes DM. Accuracy and completeness of mortality data in the Department of Veterans Affairs. Popul Health Metr 2006;4:2.
23. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Musher DM, Niederman MS, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44:S27-S72. (Pubitemid 46290553)
24. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356:775-789. (Pubitemid 46294610)
25. Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/ fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:144-149. (Pubitemid 46115085)
26. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26.
27. Barnes NC, Qiu YS, Pavord ID, Parker D, Davis PA, Zhu J, Johnson M, Thomson NC, Jeffery PK. Antiinflammatory effects of salmeterol/ fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006;173:736-743.
28. Llewellyn-Jones CG, Harris TA, Stockley RA. Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema. Am J Respir Crit Care Med 1996;153:616-621. (Pubitemid 26051337)
29. Sin DD, Lacy P, York E, Man SF. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:760-765. (Pubitemid 39298991)
30. van Overveld FJ, Demkow UA, Gorecka D, Zielinski J, De Backer WA. Inhibitory capacity of different steroids on neutrophil migration across a bilayer of endothelial and bronchial epithelial cells. Eur J Pharmacol 2003;477:261-267. (Pubitemid 38366399)
31. Lekkou A, Karakantza M, Mouzaki A, Kalfarentzos F, Gogos CA. Cytokine production and monocyte HLA-DR expression as predictors of outcome for patients with community-acquired severe infections. Clin Diagn Lab Immunol 2004;11:161-167. (Pubitemid 38090671)
32. Kambas K, Markiewski MM, Pneumatikos IA, Rafail SS, Theodorou V, Konstantonis D, Kourtzelis I, Doumas MN, Magotti P, Deangelis RA, et al. C5a and TNF-alpha up-regulate the expression of tissue factor in intra-alveolar neutrophils of patients with the acute respiratory distress syndrome. J Immunol 2008;180:7368-7375.
33. Zemans RL, Colgan SP, Downey GP. Transepithelial migration of neutrophils: mechanisms and implications for acute lung injury. Am J Respir Cell Mol Biol 2009;40:519-535.
34. Barbier M, Agusti A, Alberti S. Fluticasone propionate reduces bacterial airway epithelial invasion. Eur Respir J 2008;32:1283-1288.
35. Joo MJ, Lee TA, Bartle B, van de Graaff WB, Weiss KB. Patterns of Healthcare Utilization by COPD Severity: a pilot study. Lung 2008; 186:307-312.
36. Lee TA, Bartle B, Weiss KB. Spirometry use in clinical practice following diagnosis of COPD. Chest 2006;129:1509-1515. (Pubitemid 43894979)